Interleukin-2: Clinical applications
- 1 June 2002
- journal article
- review article
- Published by Elsevier BV in Seminars in Oncology
- Vol. 29 (3), 12-17
- https://doi.org/10.1053/sonc.2002.33077
Abstract
No abstract availableKeywords
This publication has 37 references indexed in Scilit:
- Phase III Multicenter Randomized Trial of the Dartmouth Regimen Versus Dacarbazine in Patients With Metastatic MelanomaJournal of Clinical Oncology, 1999
- Phase III trial of dacarbazine versus dacarbazine with interferon alpha-2b versus dacarbazine with tamoxifen versus dacarbazine with interferon alpha-2b and tamoxifen in patients with metastatic malignant melanoma: an Eastern Cooperative Oncology Group study.Journal of Clinical Oncology, 1998
- Lymphocyte responses and cytokinesCell, 1994
- Prospective Randomized Trial of High-Dose Interleukin-2 Alone or in Conjunction With Lymphokine-Activated Killer Cells for the Treatment of Patients With Advanced CancerJNCI Journal of the National Cancer Institute, 1993
- Complete responses and long-term survivals after systemic chemotherapy for patients with advanced malignant melanomaCancer, 1989
- Interleukin 2 induction of lymphokine-activated killer (LAK) activity in the peripheral blood and bone marrow of acute leukemia patients. I. Feasibility of LAK generation in adult patients with active disease and in remissionBlood, 1988
- Regression of established pulmonary metastases and subcutaneous tumor mediated by the systemic administration of high-dose recombinant interleukin 2.The Journal of Experimental Medicine, 1985
- Biological Activity of Recombinant Human Interleukin-2 Produced in Escherichia coliScience, 1984
- Structure and expression of a cloned cDNA for human interleukin-2Nature, 1983
- Selective in Vitro Growth of T Lymphocytes from Normal Human Bone MarrowsScience, 1976